MA38454A1 - Inhibiteurs de protéines kinases - Google Patents

Inhibiteurs de protéines kinases

Info

Publication number
MA38454A1
MA38454A1 MA38454A MA38454A MA38454A1 MA 38454 A1 MA38454 A1 MA 38454A1 MA 38454 A MA38454 A MA 38454A MA 38454 A MA38454 A MA 38454A MA 38454 A1 MA38454 A1 MA 38454A1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
useful
formula
fgfr
Prior art date
Application number
MA38454A
Other languages
English (en)
Other versions
MA38454B1 (fr
Inventor
Srinivasan Rajagopalan
Prasad Appukuttan
Arumugam Karthikeyan Narasingapuram
Ravi Kotrabasaiah Ujjinamatada
Shyla George
Tero Linnanen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA38454A1 publication Critical patent/MA38454A1/fr
Publication of MA38454B1 publication Critical patent/MA38454B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i), dans laquelle r1 à r5, a, b, z, z1 et z2 étant tels que définis dans les revendications, et des sels pharmaceutiquement acceptables de celui-ci. Les composés de formule (i) selon l'invention sont utiles en tant qu'inhibiteurs de fgfr et sont utiles dans le traitement d'une affection où l'inhibition de la fgfr kinase est souhaitée, telle que le cancer.
MA38454A 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases MA38454B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN382KO2013 2013-04-04
PCT/FI2014/000003 WO2014162039A1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Publications (2)

Publication Number Publication Date
MA38454A1 true MA38454A1 (fr) 2018-02-28
MA38454B1 MA38454B1 (fr) 2018-11-30

Family

ID=50685938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38454A MA38454B1 (fr) 2013-04-04 2014-04-03 Inhibiteurs de protéines kinases

Country Status (33)

Country Link
US (1) US20160031855A1 (fr)
EP (1) EP2981533B1 (fr)
JP (1) JP6356782B2 (fr)
KR (1) KR20150138383A (fr)
CN (1) CN105073733B (fr)
AR (1) AR095781A1 (fr)
AU (1) AU2014246961B2 (fr)
BR (1) BR112015025413A2 (fr)
CA (1) CA2907855A1 (fr)
CL (1) CL2015002932A1 (fr)
CY (1) CY1120306T1 (fr)
DK (1) DK2981533T3 (fr)
EA (1) EA031076B1 (fr)
ES (1) ES2658183T3 (fr)
HR (1) HRP20180382T1 (fr)
HU (1) HUE036692T2 (fr)
LT (1) LT2981533T (fr)
MA (1) MA38454B1 (fr)
MX (1) MX2015013776A (fr)
MY (1) MY184528A (fr)
NO (1) NO2981533T3 (fr)
NZ (1) NZ713410A (fr)
PE (1) PE20160115A1 (fr)
PH (1) PH12015502284A1 (fr)
PL (1) PL2981533T3 (fr)
PT (1) PT2981533T (fr)
RS (1) RS56942B1 (fr)
SA (1) SA515361260B1 (fr)
SG (1) SG11201508125XA (fr)
SI (1) SI2981533T1 (fr)
TW (1) TWI628176B (fr)
UA (1) UA115176C2 (fr)
WO (1) WO2014162039A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
EP3275442B1 (fr) 2015-03-25 2021-07-28 National Cancer Center Agent thérapeutique contre le cancer du canal cholédoque
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
US10487863B2 (en) * 2017-02-17 2019-11-26 Ford Global Technologies, Llc Castellated joint for improved adhesive coverage when using mechanical fixings and adhesive in one joint
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3985005A4 (fr) 2019-06-14 2023-07-19 CGeneTech (Suzhou, China) Co., Ltd. Composé cyclique fusionné en tant qu'inhibiteur double de fgfr et vegfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4006027B1 (fr) 2019-07-26 2025-10-01 CGeneTech (Suzhou, China) Co., Ltd. Dérivé de pyridine servant d'inhibiteurs doubles de fgfr et vegfr pour le traitement des maladies de cancer
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3157361A1 (fr) 2019-10-14 2021-04-22 Incyte Corporation Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CA3206502A1 (fr) * 2021-01-26 2022-08-04 Zhengxia CHEN Forme cristalline de compose de pyridoimidazole substitue par un methylpyrazole et son procede de preparation
WO2022203399A1 (fr) * 2021-03-26 2022-09-29 주식회사 스탠다임 Antagoniste du récepteur a2a de l'adénosine et son utilisation
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194152A4 (fr) * 1999-06-30 2002-11-06 Merck & Co Inc Composes inhibiteurs de la kinase src
EP1206260A4 (fr) * 1999-06-30 2002-10-30 Merck & Co Inc Composes inhibiteurs de la src kinase
JP4769720B2 (ja) * 2003-08-21 2011-09-07 オーエスアイ・ファーマシューテイカルズ・エル・エル・シー Ｎ−置換ベンズイミダゾリルｃ−Ｋｉｔ阻害剤
KR20090064602A (ko) * 2006-10-16 2009-06-19 노파르티스 아게 단백질 키나제 억제제로서 유용한 페닐아세트아미드
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en) * 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2011038579A1 (fr) * 2009-09-30 2011-04-07 Zhejiang Beta Pharma Inc. Composés et compositions comme inhibiteurs de protéines kinases
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази

Also Published As

Publication number Publication date
UA115176C2 (uk) 2017-09-25
EA031076B1 (ru) 2018-11-30
CN105073733B (zh) 2017-06-27
HRP20180382T1 (hr) 2018-04-06
PH12015502284B1 (en) 2016-02-01
SI2981533T1 (en) 2018-04-30
ES2658183T3 (es) 2018-03-08
CN105073733A (zh) 2015-11-18
CY1120306T1 (el) 2019-07-10
AU2014246961B2 (en) 2017-09-28
AU2014246961A1 (en) 2015-10-22
CA2907855A1 (fr) 2014-10-09
EP2981533A1 (fr) 2016-02-10
MA38454B1 (fr) 2018-11-30
LT2981533T (lt) 2018-02-26
TW201524970A (zh) 2015-07-01
EP2981533B1 (fr) 2017-12-06
RS56942B1 (sr) 2018-05-31
PT2981533T (pt) 2018-02-27
BR112015025413A2 (pt) 2017-07-18
TWI628176B (zh) 2018-07-01
PE20160115A1 (es) 2016-03-03
KR20150138383A (ko) 2015-12-09
HK1217198A1 (zh) 2016-12-30
PL2981533T3 (pl) 2018-04-30
JP2016515604A (ja) 2016-05-30
PH12015502284A1 (en) 2016-02-01
NZ713410A (en) 2018-07-27
CL2015002932A1 (es) 2016-04-22
JP6356782B2 (ja) 2018-07-11
SA515361260B1 (ar) 2017-08-27
AR095781A1 (es) 2015-11-11
MY184528A (en) 2021-04-01
SG11201508125XA (en) 2015-10-29
DK2981533T3 (en) 2018-02-12
EA201591913A1 (ru) 2016-03-31
US20160031855A1 (en) 2016-02-04
NO2981533T3 (fr) 2018-05-05
MX2015013776A (es) 2016-02-26
HUE036692T2 (hu) 2018-07-30
WO2014162039A1 (fr) 2014-10-09

Similar Documents

Publication Publication Date Title
MA38454B1 (fr) Inhibiteurs de protéines kinases
MA54327B1 (fr) Inhibiteurs de kras g12c
MA46337A (fr) Composé de pyridine
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
SA521421205B1 (ar) مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان
PH12020551464A1 (en) Cd73 inhibitors
MA45940B1 (fr) Composé hétérocyclique
MA52948B1 (fr) Composés
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA40225A (fr) Composés dihydroisoquinolinone substitués
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
UA111382C2 (uk) Інгібітори протеїнкінази
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MA39048A1 (fr) Nouveaux inhibiteurs de la dgat2
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA39983B1 (fr) Dérivés de carboxamide
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MX2022007487A (es) Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside